FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029907855> ?p ?o ?g. }

• W2029907855 endingPage "2024" @default.
• W2029907855 startingPage "2016" @default.
• W2029907855 abstract "Abstract BACKGROUND. Cleavage of membrane‐anchored heparin‐binding epidermal growth factor‐like growth factor (proHB‐EGF) yields a soluble HB‐EGF isoform (sHB‐EGF), which is an activating epidermal growth factor receptor (EGFR) ligand and a C‐terminal fragment HB‐EGF‐C acting directly in the nucleus. In bladder cancer, overexpression of both HB‐EGF and EGFR have been observed, but to the authors' knowledge the prognostic significance of different modes of HB‐EGF signaling have remained unclear. METHODS. Expression and intracellular localization of HB‐EGF and EGFR were examined by immunohistochemistry in paraffin‐embedded specimens from 121 patients who underwent cystectomy for bladder cancer. Tumor stage was pTis/pT1 in 7 patients, pT2 in 41 patients, pT3 in 55 patients, and pT4 in 18 patients. Lymph node metastases were present in 32 patients. RESULTS. Using an antibody directed against the C‐terminal domain, HB‐EGF expression was detected in the cytoplasm or in the nucleus of tumor cells. EGFR staining was uniform at the plasma membrane. The actuarial 5‐year cancer‐specific survival of patients with tumors with predominant nuclear HB‐EGF staining was 28% compared with 57% if HB‐EGF staining was predominantly cytoplasmic ( P = .027). Disease outcome of patients with a ‘mixed’ HB‐EGF staining pattern was found to be between that of the 2 former groups. In agreement with previous studies, strong EGFR expression was associated with poor prognosis. Despite strong EGFR expression, predominant cytoplasmic HB‐EGF staining was associated with a more favorable outcome, whereas a predominant nuclear pattern defined a subgroup with extremely poor prognosis (5‐year tumor‐specific survival of 55% vs 13%, respectively; P = .026). CONCLUSIONS. The current study results confirm that EGFR expression is significantly correlated with disease‐specific mortality but that the outcome is also influenced by the mode of HB‐EGF signaling. Additional nuclear HB‐EGF signaling, indicative of increased cleavage of proHB‐EGF, appears to enhance the adverse activities. Cytoplasmic HB‐EGF staining likely reflects proHB‐EGF, which may also exert antiproliferative effects. Cancer 2007. © 2007 American Cancer Society." @default.
• W2029907855 created "2016-06-24" @default.
• W2029907855 creator A5039660568 @default.
• W2029907855 creator A5043709668 @default.
• W2029907855 creator A5062139994 @default.
• W2029907855 creator A5066148411 @default.
• W2029907855 creator A5069810248 @default.
• W2029907855 creator A5070132278 @default.
• W2029907855 date "2007-03-29" @default.
• W2029907855 modified "2023-10-12" @default.
• W2029907855 title "Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome" @default.
• W2029907855 cites W1426844501 @default.
• W2029907855 cites W1517120488 @default.
• W2029907855 cites W179748458 @default.
• W2029907855 cites W1998358446 @default.
• W2029907855 cites W2002593980 @default.
• W2029907855 cites W2007577818 @default.
• W2029907855 cites W2033021780 @default.
• W2029907855 cites W2033470244 @default.
• W2029907855 cites W2036236716 @default.
• W2029907855 cites W2041042026 @default.
• W2029907855 cites W2049022471 @default.
• W2029907855 cites W2049130091 @default.
• W2029907855 cites W2051120695 @default.
• W2029907855 cites W2056449387 @default.
• W2029907855 cites W2074511614 @default.
• W2029907855 cites W2083230165 @default.
• W2029907855 cites W2086324825 @default.
• W2029907855 cites W2105392824 @default.
• W2029907855 cites W2109694492 @default.
• W2029907855 cites W2132499449 @default.
• W2029907855 cites W2135552252 @default.
• W2029907855 cites W2140858291 @default.
• W2029907855 cites W2144705599 @default.
• W2029907855 cites W2158784355 @default.
• W2029907855 cites W4232995978 @default.
• W2029907855 cites W4376849078 @default.
• W2029907855 doi "https://doi.org/10.1002/cncr.22627" @default.
• W2029907855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17394193" @default.
• W2029907855 hasPublicationYear "2007" @default.
• W2029907855 type Work @default.
• W2029907855 sameAs 2029907855 @default.
• W2029907855 citedByCount "53" @default.
• W2029907855 countsByYear W20299078552012 @default.
• W2029907855 countsByYear W20299078552013 @default.
• W2029907855 countsByYear W20299078552014 @default.
• W2029907855 countsByYear W20299078552015 @default.
• W2029907855 countsByYear W20299078552016 @default.
• W2029907855 countsByYear W20299078552017 @default.
• W2029907855 countsByYear W20299078552018 @default.
• W2029907855 countsByYear W20299078552019 @default.
• W2029907855 countsByYear W20299078552020 @default.
• W2029907855 countsByYear W20299078552021 @default.
• W2029907855 countsByYear W20299078552022 @default.
• W2029907855 crossrefType "journal-article" @default.
• W2029907855 hasAuthorship W2029907855A5039660568 @default.
• W2029907855 hasAuthorship W2029907855A5043709668 @default.
• W2029907855 hasAuthorship W2029907855A5062139994 @default.
• W2029907855 hasAuthorship W2029907855A5066148411 @default.
• W2029907855 hasAuthorship W2029907855A5069810248 @default.
• W2029907855 hasAuthorship W2029907855A5070132278 @default.
• W2029907855 hasBestOaLocation W20299078551 @default.
• W2029907855 hasConcept C121608353 @default.
• W2029907855 hasConcept C126322002 @default.
• W2029907855 hasConcept C142724271 @default.
• W2029907855 hasConcept C159048773 @default.
• W2029907855 hasConcept C170493617 @default.
• W2029907855 hasConcept C204232928 @default.
• W2029907855 hasConcept C2775960820 @default.
• W2029907855 hasConcept C2776362946 @default.
• W2029907855 hasConcept C2779438470 @default.
• W2029907855 hasConcept C2780352672 @default.
• W2029907855 hasConcept C502942594 @default.
• W2029907855 hasConcept C71924100 @default.
• W2029907855 hasConcept C86803240 @default.
• W2029907855 hasConceptScore W2029907855C121608353 @default.
• W2029907855 hasConceptScore W2029907855C126322002 @default.
• W2029907855 hasConceptScore W2029907855C142724271 @default.
• W2029907855 hasConceptScore W2029907855C159048773 @default.
• W2029907855 hasConceptScore W2029907855C170493617 @default.
• W2029907855 hasConceptScore W2029907855C204232928 @default.
• W2029907855 hasConceptScore W2029907855C2775960820 @default.
• W2029907855 hasConceptScore W2029907855C2776362946 @default.
• W2029907855 hasConceptScore W2029907855C2779438470 @default.
• W2029907855 hasConceptScore W2029907855C2780352672 @default.
• W2029907855 hasConceptScore W2029907855C502942594 @default.
• W2029907855 hasConceptScore W2029907855C71924100 @default.
• W2029907855 hasConceptScore W2029907855C86803240 @default.
• W2029907855 hasIssue "10" @default.
• W2029907855 hasLocation W20299078551 @default.
• W2029907855 hasLocation W20299078552 @default.
• W2029907855 hasOpenAccess W2029907855 @default.
• W2029907855 hasPrimaryLocation W20299078551 @default.
• W2029907855 hasRelatedWork W1512940928 @default.
• W2029907855 hasRelatedWork W196351422 @default.
• W2029907855 hasRelatedWork W1993223505 @default.
• W2029907855 hasRelatedWork W2012865150 @default.
• W2029907855 hasRelatedWork W2020521634 @default.

• next